JAK1 and in situ carcinoma: CIS is rapidly induced in murine NK cells from IL-15 treatment, and the induced CIS, in turn, inhibits JAK1 by targeting it for proteasomal degradation, building a classic negative-feedback loop (Delconte et al., 2016).